Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
Trial Parameters
Brief Summary
The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.
Eligibility Criteria
Inclusion Criteria: * ≥2 years of age on the day of signing the informed consent form; * Genetic and clinical diagnosis of type 3 SMA with bi-allelic deletion of SMN1 of 5qSMA; * Hammersmith Functional Motor Scale - Expanded (HFMSE) score is between 10 and 54 at screening; * Female patients of childbearing age who are pregnant or lactating, as well as all enrolled patients （both male and female), should take effective contraceptive measures within 6 months after the treatment; * Patients or patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed. Exclusion Criteria: * Patient who has participated in any previous gene therapy research trials; * Patient who has AAV9 neutralizing antibody titer ≥1:200; * Patient who has received Nusinersen within 120 days and Risdiplam within 15 days before treatment; * Patient who requires invasive or non-invas